Floatz logo

Pucotenlimab

Macrovascular Invasion

Sun Yat-sen Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Macrovascular Invasion cohort.

Asset / SponsorPhaseRating
LENVATINIB
Sun Yat-sen University
Phase 2CCC
Atezolizumab
University Health Network, Toronto
Phase 1/2CC
Yttrium-90
University Health Network, Toronto
Phase 1/2CC

Same molecule, other indications

Pucotenlimab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
rectal carcinomaDormant
B
Indicative ·
59 / 100
View asset →
rectum adenocarcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →